Anmelden Kostenlos registrieren

Edesa Biotech % des Leerverkaufs (short % of float)

Was ist das % des Leerverkaufs (short % of float) von Edesa Biotech?

% des Leerverkaufs (short % of float) von Edesa Biotech, Inc. ist 2.65%

Was ist die Definition von % des Leerverkaufs (short % of float)?



% des Leerverkaufs (Short % of Float) ist die Menge der Aktien, die im Leerverkauf verkauft worden sind, die im Vergleich zum Float in Prozent ausgedrückt wird.

Short percentage of float, or short interest ratio, is calculated by taking the total amount of shares shorted and dividing it by the total amount of shares available for trade. It is an indirect metric of investor sentiment. When short percentage of float is high, above 40%, it implies company investors hope shares will decline in value. The percentage is used by both fundamental and technical traders to identify trends. The short percentage of float can also be calculated for entire exchanges to determine the sentiment of the market as a whole. If it is high of around five or greater for an exchange, this can be taken as a bearish signal, and vice versa.

% des Leerverkaufs (short % of float) von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Edesa Biotech

Was macht Edesa Biotech?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Unternehmen mit % des leerverkaufs (short % of float) ähnlich Edesa Biotech